| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 1861- | dietFMD, | Chemo, | Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models |
| - | in-vitro, | Colon, | CT26 | - | in-vivo, | NA, | NA |
| 1810- | dietKeto, | Oxy, | The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer |
| - | in-vivo, | Var, | NA |
| 2268- | dietMet, | Methionine dependency and cancer treatment |
| - | Review, | Var, | NA |
| 2263- | dietMet, | Methionine Restriction and Cancer Biology |
| - | Review, | Var, | NA |
| 2264- | dietMet, | Methionine restriction for cancer therapy: From preclinical studies to clinical trials |
| - | Review, | Var, | NA |
| 4984- | Dipy, | ATV, | Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop |
| - | in-vitro, | AML, | NA |
| 6273- | DL, | D-Limonene Exhibits Antiproliferative Activity Against Human Colorectal Adenocarcinoma (Caco-2) Cells via Regulation of Inflammatory and Apoptotic Pathways |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Colon, | HCT116 |
| 6277- | DL, | docx, | d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | PZ-HPV-7 |
| 6726- | DMSO, | DMSO induces apoptosis in SV40-transformed human keratinocytes, but not in normal keratinocytes |
| - | in-vitro, | NA, | NA |
| 6342- | DRE, | Mechanistic Study on the Inhibitory Effect of Dandelion Extract on Breast Cancer Cell Proliferation and Its Induction of Apoptosis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 6348- | DRE, | New prospects in oncotherapy: bioactive compounds from Taraxacum officinale |
| - | Review, | Var, | NA |
| 6326- | DRE, | MT, | Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 6317- | DRE, | The efficacy of dandelion root extract in inducing apoptosis in drug-resistant human melanoma cells |
| - | in-vitro, | Melanoma, | A375 |
| 6318- | DRE, | Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways |
| - | vitro+vivo, | CRC, | HCT116 | - | NA, | Nor, | NCM460 |
| 6319- | DRE, | Efficient induction of extrinsic cell death by dandelion root extract in human chronic myelomonocytic leukemia (CMML) cells |
| - | in-vitro, | AML, | MV411 | - | in-vitro, | AML, | HL-60 |
| 6320- | DRE, | Selective induction of apoptosis and autophagy through treatment with dandelion root extract in human pancreatic cancer cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 6322- | DRE, | LGE, | Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate Cancer |
| - | vitro+vivo, | Pca, | DU145 |
| 6327- | DRE, | Effect of Methanolic Extract of Dandelion Roots on Cancer Cell Lines and AMP-Activated Protein Kinase Pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| 6354- | DRE, | Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture |
| - | Review, | AML, | NA |
| 6352- | DRE, | Investigation of the Anti-Lung Cancer Mechanisms of Taraxacum officinale Based on Network Pharmacology and Multidimensional Experimental Validation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | L929 |
| 6363- | DRE, | Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review |
| - | in-vitro, | CRC, | NA |
| 4915- | DSF, | Cu, | Disulfiram: A novel repurposed drug for cancer therapy |
| - | Review, | Var, | NA |
| 5008- | DSF, | Cu, | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis |
| - | in-vitro, | HCC, | NA |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| 6801- | EA, | A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury |
| - | vitro+vivo, | BC, | 4T1 |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 6617- | Ech, | Echinacea Angustifolia DC Extract Induces Apoptosis and Cell Cycle Arrest and Synergizes with Paclitaxel in the MDA-MB-231 and MCF-7 Human Breast Cancer Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 1514- | EGCG, | Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 |
| 1503- | EGCG, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1515- | EGCG, | Phen, | Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | BT20 |
| 3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
| - | Review, | Var, | NA |
| 3214- | EGCG, | EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway |
| - | in-vitro, | Nor, | MRC-5 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
| 2309- | EGCG, | Chemo, | Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HPNE | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
| 5223- | EMD, | Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Nor, | CCD841 |
| 5519- | EP, | Nanosecond Pulsed Electric Fields (nsPEFs) for Precision Intracellular Oncotherapy: Recent Advances and Emerging Directions |
| - | Review, | Var, | NA |
| 5520- | EP, | Nanosecond Pulsed Electric Field (nsPEF): Opening the Biotechnological Pandora’s Box |
| - | Review, | Var, | NA |
| 6576- | EU, | Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53 |
| - | in-vitro, | HCC, | HepG2 |
| 6578- | EU, | Eurycomanol and eurycomanone as potent inducers for cell-cycle arrest and apoptosis in small and large human lung cancer cell lines |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 |
| 6579- | EU, | Eurycomanone and Eurycomanol from Eurycoma longifolia Jack as Regulators of Signaling Pathways Involved in Proliferation, Cell Death and Inflammation |
| - | in-vitro, | AML, | K562 |
| 6584- | EU, | Eurycoma longifolia: an overview on the pharmacological properties for the treatment of common cancer |
| - | Review, | Var, | NA |
| 6377- | Eug, | Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6389- | Eug, | Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review |
| - | Review, | Colon, | NA |
| 6387- | Eug, | Anticancer and antibacterial effects of a clove bud essential oil-based nanoscale emulsion system |
| - | in-vitro, | Thyroid, | NA | - | in-vitro, | Nor, | HEK293 |
| 6388- | Eug, | Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review |
| - | Review, | Var, | NA |
| 2497- | Fenb, | In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells |
| - | in-vitro, | GBM, | NA |
| 2496- | Fenb, | Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 6426- | FEO, | Foeniculum Vulgare and Pelargonium Graveolens Essential Oil Mixture Triggers the Cell Cycle Arrest and Apoptosis in MCF-7 Cells |
| - | in-vitro, | BC, | MCF7 |
| 2851- | FIS, | Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid